Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke

Inclusion Criteria: * Acute ischemic stroke * Able to receive thrombolysis, mechanical thrombectomy or both * National Institutes of Health Stroke Scale (NIHSS) score of ≥ 5 * Signed informed consent * Agreement to use effective birth control throughout the study Exclusion Criteria: * Neurologic deficit is non-disabling * History of stroke or penetrating head injury within 90 days prior to enrollment * History of previous or current diagnosis of intracranial hemorrhage * Moyamoya disease, cerebral arteriovenous malformation, or known unsecured aneurysm requiring intervention during the acute study period * Presence of tandem lesions suggesting a likely need for proximal artery stenting during the thrombectomy procedure that would mandate post-operative dual antiplatelet therapy * Presence of other neurological or non-neurological co-morbidities, independently of the current stroke, that may lead to further deterioration in the subject's neurological status during the study period * Prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT) * Severe hypertension or hypotension * Blood glucose concentration \< 50 mg/dL * Prior exposure to any exogenous form of a recombinant variant of human APC